This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G61.8 | Special Copayment Reduction: V126 | Coverage period: 5 years |
| B. Synonyms | Chronic inflammatory demyelinating polyneuropathy (CIDP), chronic relapsing polyneuropathy, chronic GBS, chronic inflammatory polyradiculoneuropathy |
| C. Adult onset | Likelihood of first onset in adulthood high — median age of onset about 47 years; pediatric onset is possible but most are adults |
| 1. History | 1958: Austin described chronic relapsing neuropathy; 1975: Dyck et al. established CIDP as an independent disease; 1980s~90s: systematization of treatment and diagnostic criteria |
| 2. Causes | Autoimmune mechanism; T-cell- and B-cell-mediated myelin damage; autoantibodies such as anti-nodal/paranodal (NF155·NF186) and anti-contactin 1 antibodies identified in some |
| 3. Genetics | Non-hereditary; studies of HLA associations (HLA-DR·DQ, etc.); a specific clinical subtype associated with anti-NF155 IgG4 has been described |
| 4. General epidemiology | Prevalence about 1~9/100,000; incidence about 0.2~1.6/100,000/year; slight male predominance; more common from middle age |
| 5. Pathophysiology | T-cell-mediated myelin invasion, autoantibodies (complement activation·antibody-dependent cytotoxicity), macrophage infiltration; anti-nodal/paranodal antibodies directly damage nodal structures |
| 6. Symptoms | Symmetric limb weakness and sensory disturbance progressing for 8 weeks or more; relapsing-remitting or progressive course; sensory loss predominantly of vibration·position sense; gait disturbance |
| 7. Signs | Generalized reduction·loss of tendon reflexes, proximal and distal muscle weakness, sensory conduction abnormalities (vibration·position sense), distal limb sensory loss, nerve hypertrophy (in some) |
| 8. Screening | Nerve conduction studies first when demyelinating neuropathy progressing for 8 weeks or more or relapsing is suspected; antibody panel and cerebrospinal fluid examination in parallel |
| 9. Diagnosis | EAN/PNS 2023 revised diagnostic criteria; nerve conduction studies (demyelinating pattern), cerebrospinal fluid (elevated protein), antibody testing (NF155·NF186·CNTN1), nerve biopsy (if needed) |
| 10. Treatment | IVIG, steroids, and plasma exchange are all effective standard treatments; 2024 FDA approval of efgartigimod alfa (FcRn blocker); maintenance immunosuppressive therapy |
| 11. Prognosis | Treatment response in about 60~70%; 30% refractory to standard treatment; cure is rare and long-term treatment is needed; the anti-NF155 IgG4 subtype responds poorly to steroids |
| 12. Prevention | No specific prevention; minimize irreversible damage with early diagnosis·treatment; manage comorbidities such as diabetes·MGUS; prevent relapse with treatment monitoring |
| References | 10 key references (including PMID/DOI) |
The concept of CIDP originates from Austin's 1958 description of a steroid-responsive chronic relapsing neuropathy. However, it was established as an independent clinical entity in 1975, when Dyck, Lais, Ohta, and colleagues at the Mayo Clinic analyzed 53 patients and reported it as "chronic inflammatory polyradiculoneuropathy." They proposed as the main diagnostic criteria a progressive course of 8 weeks or more, a demyelinating nerve conduction pattern, elevated cerebrospinal fluid protein, and inflammatory findings on nerve biopsy.
In the 1980s~1990s, randomized controlled trials demonstrating the efficacy of steroids, plasma exchange, and IVIG were published, and all three treatments became established as standard treatments for CIDP. Since the 2000s, the diagnostic criteria have been revised repeatedly, most notably in the 2023 revision of the joint EAN (European Academy of Neurology)/PNS (Peripheral Nerve Society) diagnostic criteria. From the 2010s, new autoantibodies such as anti-NF155 (neurofascin 155), anti-NF186, anti-contactin 1 (CNTN1), and anti-contactin-associated protein (CASPR1) were successively shown to be associated with CIDP subtypes, making it clear that CIDP is a spectrum disorder rather than a single disease. In 2024, the US FDA approved subcutaneous efgartigimod alfa (an FcRn blocker) for the treatment of adult CIDP, opening a new era of treatment.
CIDP is an acquired autoimmune polyneuropathy in which immunological dysregulation, rather than a specific single cause, is central. T-cell- and B-cell-mediated autoimmune responses target myelin and structures around the nodes, causing chronic demyelination and nerve damage.
Autoantibodies identified in CIDP include anti-neurofascin 155 (NF155) IgG4, anti-neurofascin 186 (NF186) IgG4, anti-contactin 1 (CNTN1) IgG4, and anti-CASPR1 IgG4. Each of these antibodies is associated with a distinctive clinical phenotype. For example, anti-NF155 IgG4 antibodies are associated with a subtype in young men characterized by severe motor impairment, cerebellar ataxia, and tremor, and this subtype often does not respond to IVIG but responds to rituximab. However, these specific autoantibodies are detected in only about 10~15% of all CIDP patients, and in the remaining patients immune-mediated mechanisms are at work but the exact antigen targets are still unclear.
Some CIDP takes a secondary form occurring in association with systemic diseases such as diabetes, MGUS (monoclonal gammopathy of undetermined significance), lymphoma, HIV infection, and hepatitis. Relapse after pregnancy and surgery has been reported.
CIDP is not a genetic disease following Mendelian inheritance. However, there are studies suggesting that genetic background may influence the regulation of immune responses and susceptibility to disease. Familial occurrence is very rare and not at a clinically meaningful level.
HLA association studies have reported that some HLA-DR·DQ alleles are associated with CIDP risk, but the results are inconsistent across ethnicities and study methods. In the anti-NF155 IgG4 antibody-positive CIDP subtype, a stronger association with specific HLA alleles (such as HLA-DRB1*15:01) has been suggested, and the possibility that this subtype forms a genetically homogeneous group is being studied. Studies of B-cell regulatory gene polymorphisms related to the development of IgG4-subtype CIDP are also underway. Clinically, there is currently no indication for genetic testing of family members of CIDP patients.
CIDP is classified as a rare disease but is relatively common among peripheral neuropathies. Prevalence ranges widely, from 1~9 per 100,000 population depending on the study, and varies greatly depending on how the diagnostic criteria are applied. Incidence is estimated at about 0.2~1.6 per 100,000 population per year.
The median age of onset is about 47 years, and it occurs most commonly in the 50s~70s. Pediatric onset is possible (about 5~10% of the total), and tends to have a more monophasic course and better steroid response than in adults. There is a slight male predominance (M:F = 1.5~2:1), and this sex ratio difference may vary by age. It occurs worldwide, with relatively less data from Asia and Africa than from the West. Since CIDP often takes an average of 1~2 years or more to diagnose, the actual prevalence is likely underestimated.
The pathophysiology of CIDP is multilayered, with T-cell- and B-cell-mediated autoimmune responses acting in combination.
T-cell-mediated mechanism: Autoreactive T cells cross the blood-nerve barrier and infiltrate the endoneurium. These T cells recognize myelin-related proteins (P0, PMP22, P2, etc.) as targets and secrete inflammatory cytokines (TNF-α, IFN-γ, IL-17), causing Schwann cell damage and myelin destruction. Reduced function of regulatory T cells (Treg) is also implicated as a cause of failure to regulate the inflammatory response.
B-cell and antibody-mediated mechanism: Autoantibodies (anti-myelin protein, anti-NF155·NF186·CNTN1·CASPR1 IgG4, etc.) directly damage myelin and paranodal structures of the nodes of Ranvier by activating complement or through antibody-dependent cellular cytotoxicity (ADCC). IgG4-subtype antibodies have low complement-activating ability but cause conduction block by blocking the function of node of Ranvier structural proteins.
Macrophage infiltration: Endoneurial macrophages phagocytose·destroy myelin (myelin stripping, vesicular myelin disruption), and repeated demyelination-remyelination (onion bulb formation) is the pathological hallmark of chronic progression.
Breakdown of the blood-nerve barrier: When the blood-nerve barrier breaks down due to abnormalities of endoneurial vascular endothelial cell junctions, immune cells and autoantibodies penetrate the endoneurium more easily.
The defining feature of CIDP is a demyelinating polyneuropathy that progresses for 8 weeks or more or repeatedly relapses and remits. This distinguishes it from GBS, which reaches maximum weakness within 4 weeks. Cases with subacute progression over 4~8 weeks are sometimes separately named subacute inflammatory demyelinating polyneuropathy (SIDP).
Motor symptoms: Symmetric limb weakness is typical. Both proximal and distal muscles are involved, and prominent proximal involvement is the main difference from GBS and other peripheral neuropathies. Both lower and upper limbs are weakened, and gait disturbance is a common initial chief complaint. Cranial nerve involvement (facial nerve, bulbar nerves) occurs rarely. Respiratory muscle involvement is rare.
Sensory symptoms: Numbness, paresthesia, and sensory loss in the limbs occur. Impairment of vibration and position sense (proprioception) tends to be more prominent than impairment of pain·temperature sense, reflecting predominant large fiber involvement. Unsteady gait due to sensory ataxia is also common.
Pain: Neuropathic pain may occur but is less prominent than in GBS. Some patients report pain as a main symptom.
Clinical course: There are three patterns: chronic progressive (about 30%), relapsing-remitting (about 30%), and monophasic (about 40%). The relapsing-remitting type repeatedly worsens after spontaneous remission and responds well to treatment. The chronic progressive type tends to progress continuously despite treatment.
The main signs on physical examination are as follows and are important for differentiation from other peripheral neuropathies.
Tendon reflex abnormalities: Generalized reduction or loss of tendon reflexes is typical. Similar to GBS, but in CIDP the loss tends not to be limited distally, with proximal reflexes (biceps, triceps reflexes) also lost.
Pattern of weakness: Symmetric limb weakness involving both proximal and distal muscles. Prominent proximal involvement is a characteristic finding of CIDP. The upper limbs may be more severely affected than the lower limbs, and depending on the subtype it varies, including pure sensory, motor-predominant, and DADS (distal acquired demyelinating symmetric neuropathy).
Sensory abnormalities: Stocking-glove distribution sensory loss and reduced vibration·position sense are prominent. Positive Romberg test (sensory ataxia). Pain·temperature sense relatively preserved.
Nerve hypertrophy: In some patients, abnormally thickened peripheral nerves are identified by palpation or MRI/ultrasound (especially the cervical plexus, ulnar nerve, peroneal nerve). Nerve hypertrophy reflects a chronic relapsing course.
Other: Papilledema (rarely), tremor (anti-NF155 IgG4 subtype), and cerebellar ataxia (anti-NF155 subtype) may be present in specific subtypes.
Screening for CIDP starts from clinical suspicion. CIDP should be considered in patients with symmetric limb weakness·sensory abnormalities progressing for 8 weeks or more or relapsing, and suspicion increases particularly when accompanied by reduced·absent tendon reflexes.
Basic screening tests: Nerve conduction studies (NCS) are the most important screening tool. Confirming a demyelinating pattern (reduced conduction velocity, F-wave delay, prolonged distal latency, conduction block) is key. Also included are serum protein electrophoresis and immunofixation electrophoresis (to exclude MGUS), blood glucose and HbA1c (to exclude diabetic neuropathy), vitamin B12, thyroid function, HIV and hepatitis serology, and an antibody panel including anti-NF155·NF186·CNTN1.
Diagnostic algorithm: The 2023 EAN/PNS diagnostic criteria present a new hierarchical approach integrating definite·possible·supportive electrophysiological findings, clinical presentation, and biomarkers. Confirmation of treatment response (clinical improvement with steroids·IVIG) is also used as supporting evidence for the diagnosis.
The diagnosis of CIDP is made by integrating clinical, electrophysiological, cerebrospinal fluid, serological, and histological tests, applying the 2023 revised EAN/PNS diagnostic criteria.
Nerve conduction studies (NCS): For definite CIDP, demyelination criteria must be met in 2 or more nerves. Demyelination criteria: ① motor conduction velocity <75% of the lower limit of normal, ② distal latency >130% of the upper limit of normal, ③ minimum F-wave latency >130% of the upper limit of normal, ④ conduction block (proximal/distal CMAP area ratio <50%). Sensory nerve conduction abnormalities (reduced or absent SNAP) are also supportive findings.
Cerebrospinal fluid examination: Elevated protein (generally 45 mg/dL or more, often 100 mg/dL or more) with a normal cell count (less than 10/μL) is typical. Albuminocytologic dissociation supports the diagnosis of CIDP. If the cell count is increased, infectious or malignant meningitis is differentiated.
Autoantibody testing: Testing for anti-NF155 IgG4, anti-NF186 IgG4, anti-CNTN1 IgG4, and anti-CASPR1 IgG4 is useful for diagnosing specific subtypes and selecting treatment (predicting rituximab response). These antibodies are important for identifying subtypes that do not respond to IVIG.
Nerve MRI and ultrasound: T2 hyperintensity and hypertrophy of the plexuses and nerves support the diagnosis of CIDP. Nerve ultrasound is highly accessible and is usefully employed to confirm nerve hypertrophy. Spinal MRI is sometimes needed to exclude spinal cord lesions or compression.
Nerve biopsy: Sural nerve biopsy shows demyelination-remyelination findings (onion bulb formation), macrophage infiltration, and lymphocyte infiltration. Biopsy is performed selectively when the diagnosis is uncertain and is not always necessary.
In CIDP, IVIG, steroids, and plasma exchange are all established as effective standard treatments. Which of the three to choose first is decided considering the patient's clinical situation, comorbidities, preferences, and access to treatment.
IVIG: Induction treatment 2 g/kg (divided over 2~5 days). Maintenance treatment 0.4~1 g/kg repeated at 3~6-week intervals. As of 2024, a subcutaneous form of IVIG is also used for CIDP maintenance treatment. Rapid onset of effect (days~weeks) is an advantage.
Steroids: Oral prednisolone (starting dose 1 mg/kg/day, maximum 80 mg/day) is used for several months and then tapered slowly. Alternatively, intravenous methylprednisolone (high-dose pulse, 500~1000 mg/day for 3 days) is repeated. To minimize the adverse effects of long-term steroid use (osteoporosis, diabetes, susceptibility to infection, weight gain), tapering strategies and use of concomitant immunosuppressants are considered.
Plasma exchange (PE): The short-term effect is rapid, but because the effect is temporary, repeated sessions are needed. Management of vascular access and coagulation abnormalities is required.
Efgartigimod alfa (Vyvgart Hytrulo): FDA approved in 2024. Its mechanism lowers pathological autoantibody levels by promoting the degradation of IgG antibodies through blockade of the neonatal Fc receptor (FcRn). Subcutaneous administration offers high convenience. Its effect in reducing relapses in relapsing-remitting CIDP has been demonstrated in a clinical trial.
Maintenance immunosuppressive therapy: Azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, and others are used for steroid-sparing effects or in treatment-refractory cases. Rituximab is effective in anti-NF155·CNTN1 IgG4-positive subtypes.
Monitoring of treatment response: Functional changes are assessed regularly with standardized scales such as I-RODS (Inflammatory Rasch-built Overall Disability Scale) and ONLS (Overall Neuropathy Limitations Scale). If there is no response or worsening, switching treatment is considered.
The prognosis of CIDP varies by clinical subtype, treatment response, and the degree of nerve damage at onset. Overall, about 60~70% of patients respond to standard treatment, but complete remission (maintaining normal function without treatment) is achieved by a minority. About 30% of patients are treatment-refractory, showing an insufficient response to standard treatment (IVIG·steroids·plasma exchange).
Prognosis by clinical course: the monophasic course has a high likelihood of complete recovery. The relapsing-remitting type recovers with treatment at each relapse, but residual disability accumulates with repeated relapses. The chronic progressive type has the poorest prognosis, with continued functional decline despite long-term treatment. Anti-NF155 IgG4- and anti-CNTN1 IgG4-positive subtypes tend to be refractory to IVIG·steroids and to have a poor prognosis but respond to rituximab. Overall mortality is not higher than in the general population, but reduced quality of life due to severe disability, depression, and chronic pain are the main sources of morbidity. In long-term follow-up of up to 5~10 years, meaningful disability in daily activities remains in about 30% of patients.
No specific method of preventing the development of CIDP is currently known, because the genetic·environmental factors that increase the risk of disease have not yet been sufficiently identified. Prevention strategies focus mainly on early diagnosis, maintenance of optimal treatment, and prevention of relapse.
Early diagnosis and treatment: Because diagnosis of CIDP is often delayed, it is important to systematically check for a demyelinating pattern in patients with peripheral neuropathy. Since early treatment minimizes the accumulation of irreversible axonal damage, preventing diagnostic delay is an important preventive goal.
Management of comorbidities: Secondary causative diseases that may be associated with CIDP, such as MGUS, diabetes, and HIV, are actively managed. When it overlaps with diabetes-related neuropathy, glycemic control is important for preserving nerve function.
Relapse monitoring: Regular neurological follow-up is essential for assessing treatment response and detecting relapse early. Early recognition of relapse and prompt treatment maximize recovery and minimize residual disability. Patient education (prompt visit to a medical facility when symptoms worsen) also contributes to early detection of relapse.